Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06313528 · ClinicalTrials.gov registry record · Phase 1
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT06313528 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 85 participants.
The verdict
NCT06313528, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
Interventions
- OTHER Placebo
- DRUG LY3437943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06313528
The ClinicalTrials.gov registry entry for NCT06313528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06313528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06313528 about?
NCT06313528 is a clinical study titled "A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943". The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
What is the current status of trial NCT06313528?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-03-20. Estimated completion is 2025-08-26.
What interventions are being tested in trial NCT06313528?
The interventions under investigation include: Placebo (OTHER), LY3437943 (DRUG).
Who is sponsoring clinical trial NCT06313528?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.